NCT05933525Phase 2Completed

Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.

Study sponsor: Immuron Ltd. · IMRN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-07-01Actual
Enrollment · participants63Actual
Source updated2026-06-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To Measure the Protective Efficacy of Oral Administration of Travelan Compared to Placebo Against Moderate-to-severe Diarrhea Following With E.Coli (ETEC) Challenge.. After: Measure: Protective Efficacy of a Single Daily Dose of Travelan Against Moderate-to-severe Diarrhea Following Challenge With Enterotoxigenic E. Coli (ETEC) Strain H10407..

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To measure the protective efficacy of oral administration of Travelan compared to placebo against moderate-to-severe diarrhea following with E.coli (ETEC) challenge.. After: Measure: To Measure the Protective Efficacy of Oral Administration of Travelan Compared to Placebo Against Moderate-to-severe Diarrhea Following With E.Coli (ETEC) Challenge..

Actual enrollment increased by 3 participants

Before: 60 participants (actual). After: 63 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview